Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, and Avicenna.AI, a leading provider of AI-based medical imaging solutions, announced that Viz.ai is integrating Avicenna.AI’s CINA-iPE and CINA-ASPECTS tools into the Viz.ai OneTM platform. The combination of Avicenna.AI’s two AI-based algorithms with Viz.ai’s care coordination capabilities provides radiologists and specialists with additional insights from computed tomography (CT) scans, to advance fast and accurate decision-making, driving better patient care.
“By integrating CINA-iPE and CINA-ASPECTS into Viz.ai One, we are providing clinicians with an even more robust, all-in-one neurovascular solution that they can trust. This can help speed up the decision-making process and ensure that patients receive appropriate treatment as quickly as possible.”
HealthTech Insights: Forian Partners With Databricks to Expand Access to Advanced Healthcare Analytics
“This expanded partnership with Avicenna.AI represents an important step forward in our mission to improve patient care through AI-powered, clinical workflows,” said Justin Ryea, director of product at Viz.ai. “By integrating CINA-iPE and CINA-ASPECTS into Viz.ai One, we are providing clinicians with an even more robust, all-in-one neurovascular solution that they can trust. This can help speed up the decision-making process and ensure that patients receive appropriate treatment as quickly as possible.”
The CINA-ASPECTS tool automatically assesses the ASPECTS (Alberta Stroke Program Early CT Score) from CT brain images, providing an objective and reliable measure of stroke severity. Avicenna.AI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CINA-iPE and CINA-ASPECTS tools in March 2024. The CINA-iPE tool detects incidental pulmonary embolism (PE), a life-threatening blockage in a lung artery, during routine CT scans and is intended to address delayed and missed findings. Unsuspected PE is a common finding in routine CT scans of the chest, but as little as 25% of emboli are reported during the initial interpretation. By combining Avicenna.AI’s technology with Viz.ai One, which facilitates real-time communication and coordination among care teams, clinicians can make faster, more informed decisions about treatment options for patients in need.
HealthTech Insights: Carestream Secures Crucial Business Partner Agreement in Algeria
“We are thrilled to further our partnership with Viz.ai,” said Cyril Di Grandi, CEO of Avicenna.AI. “Incorporating CINA-iPE and CINA-ASPECTS into Viz.ai’s platform will allow us to bring a higher level of quality and efficiency to patient care. Our shared goal of empowering healthcare professionals with innovative tools to make critical decisions quickly and confidently can improve outcomes for more patients by helping to diagnose life-threatening conditions faster and facilitating appropriate follow-up care to patients when they need it.”
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – businesswire
